Sequence-Activated Fluorescent Nanotheranostics for Real-Time Profiling Pancreatic Cancer

• Published in: JACS Au Vol. 2; no. 1; pp. 246 - 257
• Main Authors: Tao, Yining, Yan, Chenxu, Li, Dan, Dai, Jianfeng, Cheng, Yingsheng, Li, Hui, Zhu, Wei-Hong, Guo, Zhiqian
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 24.01.2022
• Subjects: nanotheranostics; aggregation-induced emission; near-infrared fluorescence; pancreatic ductal adenocarcinoma; sequence-activated
• ISSN: 2691-3704; 2691-3704
• DOI: 10.1021/jacsau.1c00553

Pancreatic ductal adenocarcinoma (PDAC), as one of the most malignant tumors with dense desmoplastic stroma, forms a specific matrix barrier to hinder effective diagnosis and therapy. To date, a paramount challenge is in the search for intelligent nanotheranostics for such hypopermeable tumors, especially in breaking the PDAC-specific physical barrier. The unpredictable in vivo behaviors of nanotheranostics, that is, real-time tracking where, when, and how they cross the physical barriers and are taken up by tumor cells, are the major bottleneck. Herein, we elaborately design sequence-activated nanotheranostic TCM-U11&Cy@P with dual-channel near-infrared fluorescence outputs for monitoring in vivo behaviors in a sequential fashion. This nanotheranostic with a programmable targeting capability effectively breaks through the PDAC barriers. Ultimately, the released aggregation-induced emission (AIE) particle TCM-U11 directly interacts with PDAC cells and penetrates into the deep tissue. Impressively, this fluorescent nanotheranostic intraoperatively can map human clinical PDAC specimens with high resolution. We believe that this unique sequence-activated fluorescent strategy expands the repertoire of nanotheranostics in the treatment of hypopermeable tumors.